Insmed Incorporated

NasdaqGS:INSM

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 27.88 B

Share Price

USD 131.88

Avg Daily Volume

3,923,959

Change (1 day)

-0.54%

Change (1 year)

66.92%

Change (YTD)

91.02%

Insmed Incorporated Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2025: -195.37%

Insmed Incorporated Return on Equity (ROE) is -195.37% for the Trailing 12 Months (TTM) ending June 30, 2025. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Insmed Incorporated Return on Equity (ROE) for the Trailing 12 Months (TTM) ending June 30, 2023 was 1,954.53%.

Competitors

Mineralys Therapeutics, Inc.

USD 14.88

MLYS

+0.28 1.88%

Halozyme Therapeutics, Inc.

USD 71.82

HALO

+0.21 0.29%

Cytokinetics, Incorporated

USD 38.34

CYTK

+0.29 0.76%

PTC Therapeutics, Inc.

USD 50.57

PTCT

+1.65 3.37%

Amicus Therapeutics, Inc.

USD 7.61

FOLD

+0.01 0.13%

Inhibrx Biosciences, Inc.

USD 25.00

INBX

+0.84 3.48%

Legend Biotech Corporation

USD 35.56

LEGN

+0.03 0.08%

Ultragenyx Pharmaceutical Inc.

USD 29.78

RARE

+0.26 0.88%

View all

Key Data

Date	Return on Equity (ROE)	Return on Assets (ROA)	Revenue Per Share	Free Cash Flow Per Share